Mesoblast shows potential in Type 1 diabetes

Company News

Mesoblast Limited (ASX:MSB) has announced the company has exclusively licensed patented technology that modifies adult stem cells to enhance their natural homing properties to sites of excessive inflammation.
 
The stem cell technology has successfully induced durable reversal of Type 1 diabetes in a pre-clinical study.
 
The results showed that when the stem cell technology reached the inflamed pancreas of diabetic mice, those mice reverted to having normal blood glucose.
 
The company says Type 1 diabetes continues to increase in people under 20, making innovative new treatments a major strategic focus for the pharmaceutical industry.
 
Mesoblast reported a net loss of $48.57 million at 31 December 2015. 

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?